JP2015091877A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015091877A5 JP2015091877A5 JP2015021023A JP2015021023A JP2015091877A5 JP 2015091877 A5 JP2015091877 A5 JP 2015091877A5 JP 2015021023 A JP2015021023 A JP 2015021023A JP 2015021023 A JP2015021023 A JP 2015021023A JP 2015091877 A5 JP2015091877 A5 JP 2015091877A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- amount
- present
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 10
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 10
- 239000008213 purified water Substances 0.000 claims 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 9
- 239000002904 solvent Substances 0.000 claims 8
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 5
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 5
- 239000006068 taste-masking agent Substances 0.000 claims 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 4
- 235000011187 glycerol Nutrition 0.000 claims 4
- 239000007788 liquid Substances 0.000 claims 4
- 159000000000 sodium salts Chemical class 0.000 claims 4
- 229960004998 Acesulfame potassium Drugs 0.000 claims 3
- WBZFUFAFFUEMEI-UHFFFAOYSA-N Acesulfame potassium Chemical compound [K+].CC1=CC(=O)NS(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-N 0.000 claims 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 3
- 235000010358 acesulfame potassium Nutrition 0.000 claims 3
- 239000000619 acesulfame-K Substances 0.000 claims 3
- 230000002335 preservative Effects 0.000 claims 3
- 239000003755 preservative agent Substances 0.000 claims 3
- 239000000600 sorbitol Substances 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000011877 solvent mixture Substances 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N Maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims 1
- 229960004793 Sucrose Drugs 0.000 claims 1
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 239000003205 fragrance Substances 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 239000000845 maltitol Substances 0.000 claims 1
- 235000010449 maltitol Nutrition 0.000 claims 1
- 229940035436 maltitol Drugs 0.000 claims 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 229960002216 methylparaben Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 229960003415 propylparaben Drugs 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 229960002920 sorbitol Drugs 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
Claims (23)
- 式（ＩＩ）
- 前記精製水が９．１１％ｗ／ｗ〜３８．４１％ｗ／ｗの量で存在する、請求項１に記載の医薬組成物。
- 前記式（ＩＩ）の化合物が０．４０％ｗ／ｗ〜０．５０％ｗ／ｗの量で存在する、請求項１または２に記載の医薬組成物。
- 前記溶媒が９７％ｗ／ｗ、９８％ｗ／ｗまたは９９％ｗ／ｗの量で存在する、請求項１または２に記載の医薬組成物。
- 前記溶媒が６８％ｗ／ｗ、６９％ｗ／ｗまたは７０％ｗ／ｗの量で存在する、請求項１または２に記載の医薬組成物。
- 前記溶媒がプロピレングリコール、グリセリン、ＰＥＧ４００、および精製水の混合物である、請求項１または２に記載の医薬組成物。
- 前記溶媒がＰＥＧ４００、プロピレングリコール、および精製水の混合物である、請求項１または２に記載の医薬組成物。
- 前記重炭酸ナトリウムが０．４２％ｗ／ｗの量で存在する、請求項１または２に記載の医薬組成物。
- さらに１％ｗ／ｗ以下の量で存在する防腐剤を含み、ここで、該防腐剤がメチルパラベン、プロピルパラベンおよびこれらの混合物からなる群より選択される、請求項１または２に記載の医薬組成物。
- 前記防腐剤が０．２％ｗ／ｗの量で存在する、請求項９に記載の医薬組成物。
- さらに１％ｗ／ｗ以下の量で存在する界面活性剤を含み、ここで、該界面活性剤がラウリル硫酸ナトリウムである、請求項１または２に記載の医薬組成物。
- 前記界面活性剤が０．５％ｗ／ｗの量で存在する、請求項１１に記載の医薬組成物。
- さらに味覚遮蔽剤を含み、ここで、該味覚遮蔽剤がソルビトール、マルチトール、スクロース、アセスルファムカリウムおよびこれらの混合物からなる群から選択される、請求項１または２に記載の医薬組成物。
- 前記味覚遮蔽剤がソルビトールである、請求項１３に記載の医薬組成物。
- 癌を治療するための請求項１または２に記載の医薬組成物。
- 前記癌が結腸直腸癌、卵巣癌、乳癌、肺癌、胃癌、前立腺癌、膵癌、神経芽細胞腫および急性リンパ性白血病からなる群より選択される、請求項１５に記載の医薬組成物。
- 前記味覚遮蔽剤がアセスルファムカリウムである、請求項１３に記載の医薬組成物。
- 式（ＩＩ）
- 前記精製水が９．１１％ｗ／ｗ〜３８．４１％ｗ／ｗの量で存在する、請求項１８に記載の医薬組成物。
- さらに味覚遮蔽剤を含む、請求項１８または１９に記載の医薬組成物。
- 式（ＩＩ）
- 式（ＩＩ）
- 前記精製水が９．１１％ｗ／ｗ〜３８．４１％ｗ／ｗの量で存在する、請求項２１または２２に記載の医薬組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23021209P | 2009-07-31 | 2009-07-31 | |
| US61/230,212 | 2009-07-31 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012522810A Division JP2013500965A (ja) | 2009-07-31 | 2010-07-28 | 癌および他の疾患または障害の治療のための医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015091877A JP2015091877A (ja) | 2015-05-14 |
| JP2015091877A5 true JP2015091877A5 (ja) | 2015-12-17 |
| JP6014695B2 JP6014695B2 (ja) | 2016-10-25 |
Family
ID=42697590
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012522810A Pending JP2013500965A (ja) | 2009-07-31 | 2010-07-28 | 癌および他の疾患または障害の治療のための医薬組成物 |
| JP2015021023A Active JP6014695B2 (ja) | 2009-07-31 | 2015-02-05 | 癌および他の疾患または障害の治療のための医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012522810A Pending JP2013500965A (ja) | 2009-07-31 | 2010-07-28 | 癌および他の疾患または障害の治療のための医薬組成物 |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US20110039826A1 (ja) |
| EP (1) | EP2459173B1 (ja) |
| JP (2) | JP2013500965A (ja) |
| KR (1) | KR101762285B1 (ja) |
| CN (2) | CN103893186B (ja) |
| AR (1) | AR077436A1 (ja) |
| AU (1) | AU2010276741B2 (ja) |
| BR (1) | BR112012002265B8 (ja) |
| CA (1) | CA2769531C (ja) |
| CL (1) | CL2012000261A1 (ja) |
| CO (1) | CO6612185A2 (ja) |
| CR (1) | CR20120084A (ja) |
| EA (1) | EA025277B1 (ja) |
| EC (1) | ECSP12011703A (ja) |
| GE (1) | GEP201606513B (ja) |
| IL (1) | IL217839A (ja) |
| IN (1) | IN2012DN01237A (ja) |
| JO (1) | JO3434B1 (ja) |
| MA (1) | MA33533B1 (ja) |
| MX (2) | MX348197B (ja) |
| MY (1) | MY174084A (ja) |
| NZ (1) | NZ598096A (ja) |
| PE (1) | PE20120788A1 (ja) |
| SG (2) | SG10201404483VA (ja) |
| TN (1) | TN2012000046A1 (ja) |
| TW (1) | TWI522357B (ja) |
| UA (1) | UA110463C2 (ja) |
| UY (1) | UY32822A (ja) |
| WO (1) | WO2011014248A1 (ja) |
| ZA (1) | ZA201200944B (ja) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1905773E (pt) * | 2004-05-14 | 2012-10-25 | Millennium Pharm Inc | Compostos e métodos para inibir a progressão mitótica por inibição da quinase aurora |
| MX2011006725A (es) * | 2008-12-22 | 2011-09-15 | Millennium Pharm Inc | Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20. |
| JO3635B1 (ar) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| JO3434B1 (ar) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| TWI392514B (zh) * | 2010-01-29 | 2013-04-11 | Colgate Palmolive Co | 具有高微生物效力之不含氟化物及陰離子表面活性劑的潔牙劑 |
| US8653064B2 (en) | 2010-02-19 | 2014-02-18 | Millennium Pharmaceuticals, Inc. | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate |
| TW201316991A (zh) | 2011-06-03 | 2013-05-01 | Millennium Pharm Inc | Ｍｅｋ抑制劑與奧諾拉（ａｕｒｏｒａ）ａ激酶選擇性抑制劑之組合 |
| US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
| CN105209042B (zh) | 2013-03-22 | 2019-03-08 | 米伦纽姆医药公司 | 催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合 |
| EP3076963A4 (en) | 2013-12-06 | 2017-09-13 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd30 antibodies |
| JP2018524292A (ja) | 2015-07-21 | 2018-08-30 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | オーロラキナーゼインヒビターと化学療法剤の投与 |
| USD797120S1 (en) | 2015-08-28 | 2017-09-12 | Samsung Electronics Co., Ltd. | Display screen or portion thereof with graphical user interface |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747487A (en) * | 1993-07-29 | 1998-05-05 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| US6057329A (en) | 1996-12-23 | 2000-05-02 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives |
| AU784971B2 (en) | 1999-08-11 | 2006-08-10 | Biogen Inc. | Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies |
| AU2001247726A1 (en) * | 2000-03-24 | 2001-10-08 | Baker Norton Pharmaceuticals, Inc. | Taxane-based compositions and methods of use |
| US6982253B2 (en) * | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
| PT1905773E (pt) * | 2004-05-14 | 2012-10-25 | Millennium Pharm Inc | Compostos e métodos para inibir a progressão mitótica por inibição da quinase aurora |
| US20070104785A1 (en) * | 2005-07-29 | 2007-05-10 | Navale Suryakant V | Tablets of linezolid form iii and processes for their preparation |
| CA2634787C (en) * | 2005-12-23 | 2014-10-21 | Smithkline Beecham Corporation | Azaindole inhibitors of aurora kinases |
| EP2037919A2 (en) | 2006-06-30 | 2009-03-25 | Schering Corporation | Method of using substituted piperidines that increase p53 activity |
| MX2009000770A (es) * | 2006-07-21 | 2009-01-28 | Novartis Ag | Formulaciones para eteres de piridilo de bencimidazolilo. |
| JP2010500352A (ja) | 2006-08-09 | 2010-01-07 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 有糸分裂の進行を阻止するためのピリドベンゾアゼピン化合物および方法 |
| CL2007003244A1 (es) * | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| US20090203671A1 (en) * | 2007-11-27 | 2009-08-13 | Abbott Laboratories | Method of treating cancer |
| MX2011006725A (es) * | 2008-12-22 | 2011-09-15 | Millennium Pharm Inc | Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20. |
| JO3635B1 (ar) * | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| JO3434B1 (ar) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| US8653064B2 (en) * | 2010-02-19 | 2014-02-18 | Millennium Pharmaceuticals, Inc. | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate |
-
2010
- 2010-07-26 JO JOP/2010/0264A patent/JO3434B1/ar active
- 2010-07-28 NZ NZ59809610A patent/NZ598096A/en unknown
- 2010-07-28 EP EP10739413.2A patent/EP2459173B1/en active Active
- 2010-07-28 US US12/844,920 patent/US20110039826A1/en not_active Abandoned
- 2010-07-28 MX MX2015002869A patent/MX348197B/es unknown
- 2010-07-28 MY MYPI2012000438A patent/MY174084A/en unknown
- 2010-07-28 CN CN201410112836.0A patent/CN103893186B/zh active Active
- 2010-07-28 JP JP2012522810A patent/JP2013500965A/ja active Pending
- 2010-07-28 CN CN2010800415230A patent/CN102548539A/zh active Pending
- 2010-07-28 BR BR112012002265A patent/BR112012002265B8/pt active IP Right Grant
- 2010-07-28 CA CA2769531A patent/CA2769531C/en active Active
- 2010-07-28 UA UAA201202214A patent/UA110463C2/ru unknown
- 2010-07-28 IN IN1237DEN2012 patent/IN2012DN01237A/en unknown
- 2010-07-28 SG SG10201404483VA patent/SG10201404483VA/en unknown
- 2010-07-28 EA EA201270205A patent/EA025277B1/ru unknown
- 2010-07-28 MX MX2012001196A patent/MX2012001196A/es not_active Application Discontinuation
- 2010-07-28 SG SG2012005401A patent/SG177751A1/en unknown
- 2010-07-28 AU AU2010276741A patent/AU2010276741B2/en active Active
- 2010-07-28 PE PE2012000132A patent/PE20120788A1/es not_active Application Discontinuation
- 2010-07-28 GE GEAP201012599A patent/GEP201606513B/en unknown
- 2010-07-28 WO PCT/US2010/002109 patent/WO2011014248A1/en active Application Filing
- 2010-07-28 KR KR1020127004651A patent/KR101762285B1/ko active IP Right Grant
- 2010-07-30 AR ARP100102812 patent/AR077436A1/es not_active Application Discontinuation
- 2010-07-30 TW TW099125531A patent/TWI522357B/zh active
- 2010-08-02 UY UY32822A patent/UY32822A/es not_active Application Discontinuation
-
2012
- 2012-01-27 TN TNP2012000046A patent/TN2012000046A1/en unknown
- 2012-01-30 IL IL217839A patent/IL217839A/en active IP Right Grant
- 2012-01-31 CL CL2012000261A patent/CL2012000261A1/es unknown
- 2012-02-08 ZA ZA2012/00944A patent/ZA201200944B/en unknown
- 2012-02-09 CO CO12022583A patent/CO6612185A2/es not_active Application Discontinuation
- 2012-02-16 MA MA34640A patent/MA33533B1/fr unknown
- 2012-02-17 CR CR20120084A patent/CR20120084A/es unknown
- 2012-02-29 EC ECSP12011703 patent/ECSP12011703A/es unknown
-
2013
- 2013-06-11 US US13/914,705 patent/US9127011B2/en active Active
-
2015
- 2015-02-05 JP JP2015021023A patent/JP6014695B2/ja active Active
- 2015-08-28 US US14/838,878 patent/US9504693B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015091877A5 (ja) | ||
| JP2013079282A5 (ja) | ||
| JP2016503799A5 (ja) | ||
| JP2017537066A5 (ja) | ||
| CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
| JP2016515561A5 (ja) | ||
| CN106536480A8 (zh) | 吡咯烷‑2,5‑二酮衍生物、药物组合物及用作ido1抑制剂的方法 | |
| JP2016515560A5 (ja) | ||
| AR077436A1 (es) | Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos que contienen el 4-{[9-cloro-7-(2-fluoro-6-metoxifenil)-5h-pirimido-[5,4-d][2]benzacepin-2-il]amino}-2-metoxibenzoico, o una de sus sales farmaceuticamente aceptables. | |
| JP2017517565A5 (ja) | ||
| RU2015149527A (ru) | Производные доластатина 10 и ауристатинов | |
| HRP20210183T1 (hr) | 18f-obilježeni inhibitori specifičnog membranskog antigena prostate (psma) i njihova uporaba kao sredstava za vizualizaciju raka prostate | |
| RU2016122731A (ru) | Функционализированные и замещенные индолы в качестве противораковых агентов | |
| JP2017507175A5 (ja) | ||
| JP2014508804A5 (ja) | ||
| JP2015512413A5 (ja) | ||
| JP2019524883A5 (ja) | ||
| JP2019535723A5 (ja) | ||
| JP2019534265A5 (ja) | 医薬組成物およびその投与方法 | |
| JP2015098469A5 (ja) | ||
| JP2016528273A5 (ja) | ||
| EA201691342A1 (ru) | Пиразолоновые соединения и их применение | |
| JP2019519512A5 (ja) | ||
| HRP20220683T1 (hr) | Liječenje parkinsonove bolesti | |
| JP2016531846A5 (ja) |